35888-99-4

Basic information

• Product Name: 2(4-biphenyl)propionic acid
• Synonyms: 2(4-biphenyl)propionic acid;3-(4-Biphenyl)propanic acid;Biphenyl-4-propanoic acid;(1,1'-Biphenyl)-4-propanoic acid;2(para-biphenyl)propionic acid;3-([1,1'-biphenyl]-4-yl)propanoic acid;3-(4-phenylphenyl)propionic acid;3-biphenyl-4-ylpropanoic acid
• CAS NO: 35888-99-4
• Molecular Formula: C₁₅H₁₄O₂
• Molecular Weight: 226.27046
• Mol File: 35888-99-4.mol
• Article Data: 16

Chemical Properties

• Melting Point: 149-152℃
• Boiling Point: 400.4 °C at 760 mmHg
• Flash Point: 297.2 °C
• Appearance: /
• Density: 1.138 g/cm³
• Vapor Pressure: 3.94E-07mmHg at 25°C
• Refractive Index: 1.585
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.65±0.10(Predicted)
• CAS DataBase Reference: 2(4-biphenyl)propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2(4-biphenyl)propionic acid(35888-99-4)
• EPA Substance Registry System: 2(4-biphenyl)propionic acid(35888-99-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 35888-99-4(Hazardous Substances Data)

Usage

General Description

2-(4-Biphenyl)propionic acid, also known as Fenbufen, is a chemical compound often used as a non-steroidal anti-inflammatory drug (NSAID). It is commonly utilized for its analgesic and antipyretic properties in the treatment of conditions such as arthritis, tendinitis, and other musculoskeletal disorders. 2(4-Biphenyl)propionic acid has a chemical formula of C16H14O2 and a molecular weight of 242.284 g/mol. The compound belongs to the family of biphenyls and derivatives and has been associated with certain side effects such as gastrointestinal discomfort when used in medical treatments. It is not naturally occurring and must be synthesized in a laboratory.

InChI:InChI=1/C15H14O2/c16-15(17)11-8-12-6-9-14(10-7-12)13-4-2-1-3-5-13/h1-7,9-10H,8,11H2,(H,16,17)

Upstream product

• 37940-57-1 1-biphenyl-4-yl-propan-1-one 
• 63780-51-8 3-biphenyl-4-yl-propionic acid amide 
• 857803-32-8 bromo-(4-phenyl-benzyl)-malonic acid 
• 88241-65-0 4-phenylcinnamic acid 
• 124-38-9 carbon dioxide 
• 37729-56-9 4-(2-chloroethyl)-1,1'-biphenyl 
• 41900-13-4 1-Bromo-2-(4-phenylphenyl)ethane 
• 13026-23-8 (2E)-3-(1,1'-biphenyl-4-yl)acrylic acid 
• 40796-00-7 ethyl 3-([1,1′-biphenyl]-4-yl)propanoate 
• 1643-30-7 3-(4-bromophenyl)propionic acid 
• 98-80-6 phenylboronic acid 
• 81069-41-2 3-biphenyl-4-yl-acrylic acid ethyl ester 
• 3218-36-8 4-Phenylbenzaldehyde 
• 5728-52-9 (4-biphenylyl)acetic acid 

Downstream Products

• 13026-23-8 (2E)-3-(1,1'-biphenyl-4-yl)acrylic acid 
• 78733-60-5 4-(3-Hydroxypropyl)[1,1'-biphenyl] 
• 313467-78-6 (4S)-4-benzyl-3-(3-[1,1'-biphenyl-4-yl]propanoyl)-1,3-oxazolidin-2-one 
• 855959-36-3 (2R)-3-(benzyloxy)-2-([1,1'-biphenyl-4-yl]methyl)propanoic acid 
• 855959-54-5 (2S)-2-(1H-benzimidazol-2-yl)-3-[1,1'-biphenyl-4-yl]propan-1-ol 
• 855959-69-2 (2S)-3-[1,1'-biphenyl-4-yl]-2-(1H-imidazo[4,5-c]pyridin-2-yl)propan-1-ol 
• 855959-73-8 S-[(2S)-3-[1,1'-biphenyl-4-yl]-2-(1H-imidazo[4,5-c]pyridin-2-yl)propyl] ethanethioate 
• 855959-59-0 S-[(2S)-2-(1H-benzimidazol-2-yl)-3-[1,1'-biphenyl-4-yl]propyl] ethanethioate 
• 855959-49-8 2-[(1S)-2-(benzyloxy)-1-([1,1'-biphenyl-4-yl]methyl)ethyl]-1H-benzimidazole 
• 855959-64-7 2-[(1S)-2-(benzyloxy)-1-([1,1'-biphenyl-4-yl]methyl)ethyl]-1H-imidazo[4,5-c]pyridine 
• 855959-40-9 (2R)-N-(2-aminophenyl)-3-(benzyloxy)-2-([1,1'-biphenyl-4-yl]methyl)propanamide 
• 855959-45-4 (2R)-N-(3-aminopyridin-4-yl)-3-(benzyloxy)-2-([1,1'-biphenyl-4-yl]methyl)propanamide 
• 855959-31-8 (4S)-4-benzyl-3-[(2R)-3-(benzyloxy)-2-([1,1'-biphenyl-4-yl]methyl)propanoyl]-1,3-oxazolidin-2-one 
• 417699-00-4 3-bromo-6-phenylinden-1-one 

Relevant articles and documents

Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists

Structure-affinity relationship (SAR) and structure-kinetics relationship (SKR) studies were combined to investigate a series of biphenyl anthranilic acid agonists for the HCA2 receptor. In total, 27 compounds were synthesized and twelve of them showed higher affinity than nicotinic acid. Two compounds, 6g (IC50 = 75 nM) and 6z (IC50 = 108 nM) showed a longer residence time profile compared to nicotinic acid, exemplified by their kinetic rate index (KRI) values of 1.31 and 1.23, respectively. The SAR study resulted in the novel 2-F, 4-OH derivative (6x) with an IC50 value of 23 nM as the highest affinity HCA2 agonist of the biphenyl series, although it showed a similar residence time as nicotinic acid. The SAR and SKR data suggest that an early compound selection based on binding kinetics is a promising addition to the lead optimization process.

Pd-Catalyzed β-C(sp3)?H Arylation of Propionic Acid and Related Aliphatic Acids

A generally applicable Pd-catalyzed protocol for the β-C(sp3)?H arylation of propionic acid and related α-branched aliphatic acids is reported. Enabled by the use of N-acetyl-β-alanine as ligand our protocol delivers a broad range of arylation products. Notably, the highly challenging substrate, propionic acid, which lacks any acceleration through the Thorpe–Ingold effect, can be employed as substrate with synthetically useful yields. Furthermore, the scalability and synthetic applicability of the protocol are demonstrated.

Structure-activity relationship of a new series of reversible dual monoacylglycerol lipase/fatty acid amide hydrolase inhibitors

The two endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), play independent and nonredundant roles in the body. This makes the development of both selective and dual inhibitors of their inactivation an important priority. In this work we report a new series of inhibitors of monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH). Among them, (±)-oxiran-2-ylmethyl 6-(1,1′-biphenyl-4-yl)hexanoate (8) and (2R)-(-)-oxiran-2-ylmethyl(4-benzylphenyl)acetate (30) stand out as potent inhibitors of human recombinant MAGL (IC50 (8) = 4.1 μM; IC 50 (30) = 2.4 μM), rat brain monoacylglycerol hydrolysis (IC 50 (8) = 1.8 μM; IC50 (30) = 0.68 μM), and rat brain FAAH (IC50 (8) = 5.1 μM; IC50 (30) = 0.29 μM). Importantly, and in contrast to the other previously described MAGL inhibitors, these compounds behave as reversible inhibitors either of competitive (8) or noncompetitive nature (30). Hence, they could be useful to explore the therapeutic potential of reversible MAGL inhibitors.